NVCN NVCN

Neovasc Stock Price

7.84
-0.09 (-1.13%)
Upgrade to Real-Time
Afterhours (Closed)
7.84
Volume 16,032
Bid Price 7.20
Ask Price 8.18
News -
Day High 7.93

Low
0.29

52 Week Range

High
7.98

Day Low 7.56
Company Name Stock Ticker Symbol Market Type
Neovasc Inc NVCN NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.09 -1.13% 7.84 20:00:00
Open Price Low Price High Price Close Price Prev Close
7.93 7.56 7.93 7.84 7.93
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
104 16,032 $ 7.75 $ 124,325 - 0.29 - 7.98
Last Trade Time Type Quantity Stock Price Currency
16:00:00 3 $ 7.91 USD

Period:

Draw Mode:

Neovasc Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 21.40M 2.73M 2.72M $ 2.52M $ - - -0.60
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - - -

more financials information »

Neovasc News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical NVCN Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week7.697.987.007.6116,1260.151.95%
1 Month6.057.985.727.1217,6221.7929.59%
3 Months5.907.984.5856.3514,8821.9432.88%
6 Months0.44637.980.291.0693,8267.391,656.67%
1 Year0.82427.980.290.7101377294,4327.02851.23%
3 Years2.8311.490.291.66961,0145.01177.03%
5 Years108.00189.000.296.107,029,302-100.16-92.74%

Neovasc Description

Neovasc Inc is a specialty medical device company. It develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products the Neovasc Reducer (Reducer), for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and the Tiara, for the transcatheter treatment of mitral valve disease, which is under clinical investigation in the United States, Canada, Israel and Europe. The company earns revenue from one source, the Reducer.


Your Recent History
NASDAQ
NVCN
Neovasc
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to InvestorsHub
Register Now